Mallia Therapeutics Partners with Northway Biotech for Large-Scale sCD83 Manufacturing

• Mallia Therapeutics has partnered with Northway Biotech to develop and manufacture its soluble CD83 protein (sCD83), aimed at promoting hair follicle formation and growth.

• The agreement includes process development, analytical method creation, and cGMP Drug Substance production using the Pichia pastoris expression system.

Mallia Therapeutics, a biopharmaceutical company focusing on hair loss treatments, has formed a strategic collaboration with Northway Biotech (NBT), a biologics Contract Development and Manufacturing Organization (CDMO), to scale up production of its soluble CD83 protein (sCD83). The partnership aims to establish a manufacturing process to support future clinical and commercial applications.

Under the agreement, Northway Biotech will leverage its biologics manufacturing expertise to develop the production process for recombinant sCD83. This includes the implementation of analytical methods, process scale-up, and cGMP Drug Substance manufacturing, utilizing the Pichia pastoris expression system.

Dr. Manfred Groeppel, co-founder and Managing Director of Mallia Therapeutics, stated, “With this partnership, we are advancing the development of sCD83 to turn our research into a scalable treatment for patients.” Prof. Dr. Alexander Steinkasserer, co-founder and Managing Director of Mallia, noted that sCD83 not only promotes new hair follicle formation but also stimulates hair growth, making it a promising treatment for androgenetic alopecia and alopecia areata.

Prof. Vladas Algirdas Bumelis, CEO and Chairman of Northway Biotech, emphasized the company’s dedication to maintaining high manufacturing standards throughout the project. André Markmann, PhD, VP of Business Development at Northway Biotech, highlighted the collaboration as an opportunity to support an innovative treatment with global potential.